G 蛋白结合受体和肥胖症
1Cardiovascular and Metabolic Disease, Johnson & Johnson Innovative Medicine Research & Development, Spring House, PA, United States.
针对G蛋白结合受体 (GPCRs) 的新型抗肥胖药物提供了显著的减肥和心血管益处. 像葡萄糖像1受体激动剂 (GLP-1RAs) 等疗法的发展正在改变肥胖管理.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 心脏病学 心脏病学
背景情况:
- G蛋白结合受体 (GPCRs) 是慢性疾病 (如肥胖和糖尿病) 的关键药物标.
- 肥胖是一种复杂的疾病,与2型糖尿病,心脏病和癌症有关.
- 作为一种类似葡萄糖类1受体激动剂 (GLP-1RA) 的赛马格卢提德,标志着抗肥胖药物治疗的重大进步.
研究的目的:
- 审查针对GPCR向的抗肥胖药物的不断变化的治疗环境.
- 突出最近药物批准和新兴治疗策略的影响.
- 讨论肥胖药物治疗的商业影响和未来方向.
主要方法:
- 审查最近的临床试验数据和对抗肥胖药物的监管批准.
- 对针对GPCRs的药理学进展的分析.
- 对肥胖药物行业的市场分析.
主要成果:
- 作为GLP-1RA的塞马格卢提德,实现了两位数的体重减轻 (≥10%) 并证明了对心血管的益处.
- GLP-1RAs的成功刺激了新的市场参与者和投资.
- 进展包括双GIP/GLP-1激动剂,口服GLP-1配方和小分子GLP-1受体激动剂.
结论:
- 针对GPCR的向疗法,特别是GLP-1RAs,正在彻底改变肥胖治疗.
- 肥胖市场正在以创新的治疗方法扩大.
- 未来的治疗重点是组合疗法,口服配方和新型小分子,以提高疗效和患者坚持治疗.
更多相关视频
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
11:49Characterization of G Protein-coupled Receptors by a Fluorescence-based Calcium Mobilization Assay
Published on: July 28, 2014
相关概念视频
G-protein Coupled Receptors
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Transducer Mechanism: G Protein–Coupled Receptors
GPCRs are also called heptahelical,...
GPCRs Regulate Adenylyl Cylase Activity
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Activation and Inactivation of G Proteins
